X4 Pharmaceuticals, Inc

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.x4pharma.com

Safety Score

Market Cap $67.24M
PE -4
Debt $75.00M
Cash $98.20M
EV $44.04M
FCF -$125.97M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$16.76M
EBIT	-$16.67M
ROE	-28%
ROA	-9%
FCF	-$125.97M
Equity	$59.62M
Growth Stability	1
PE	-4.01
PB	1.13
P/FCF	-0.53
Price/Cash	1.46
Debt/Equity	1.26
Debt/FCF	-0.6
Net Margins	211%
Sales CAGR	0%
Equity CAGR	-6%
Earnings Growth YoY	1K%

Earnings Growth QoQ	-140%
Sales CAGR 5Y	0%
Equity CAGR 5Y	-27%
Equity CAGR 3Y	-24%
Market Cap	$67.24M
Assets	$178.17M
Total Debt	$75.00M
Cash	$98.20M
Shares Outstanding	168.51M
EV	44.04M
Safety Score	61%
Working Capital	113.71M
Current Ratio	4.89
Shares Growth 3y	35%
Equity Growth QoQ	-37%
Equity Growth YoY	-12%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.

SEC Filings

Direct access to X4 Pharmaceuticals, Inc (XFOR) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does X4 Pharmaceuticals, Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of X4 Pharmaceuticals, Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

X4 Pharmaceuticals, Inc Discounted Cash Flow

Fully customizable DCF calculator online for X4 Pharmaceuticals, Inc.

Years

Calculation mode

= -$1.3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$126M	-$1.3B
DCF		-$115M	-$104M	-$95M	-$86M	-$78M	-$71M	-$65M	-$59M	-$53M	-$49M	-$486M
Value	-$1.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-1K%	-	-2K%	-	-	-	211%
ROA	-	-39%	-92%	-32%	-48%	-73%	-56%	-69%	-9%
ROE	-	-58%	-199%	-41%	-85%	-159%	-130%	-198%	-28%

Good Net Margins (211.13%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.53	-0.28	-0.41	-0.55	-0.47	-0.44	-0.57	-0.6
Debt over Equity	-	0.25	0.53	0.15	0.46	0.53	0.46	1.08	1.26
Growth Stability	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.6)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Neutral Debt/Equity ratio (1.26)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-100%	-	-100%	-	-	0%
Earnings YoY growth	-	47%	27%	24%	16%	65%	-6%	5%	-
Equity YoY growth	-	-204%	-63%	498%	-44%	-12%	15%	-31%	-27%
FCF YoY growth	-	29%	47%	18%	25%	19%	8%	25%	-